

Table 3. Summary of pre- and post-operative outcomes, complications, recurrences, and revisions following arthroscopic treatment of hip chondromatosis.

Authors (year)	Preoperative outcomes, Mean±SD (range)	Postoperative outcomes, Mean±SD (Range)	Satisfaction rate, N (%)	Recurrence, N/N	Complications N (%) ξ	Revision, N (%) ξ
Zini et al ¹⁷ (2013)	HHS: 59 (48-72)	HHS: 87 (55-100)	Very satisfactory: 3; Satisfactory: 5; Moderately satisfactory: 2	0	0 (0%)	0 (0%)
Liu et al ²⁶ (2020)	VAS: 5.9±0.9 mHHS: 36.4±7.1 iHOT12: 69.7±12.7	VAS: 2.2±1.1 mHHS: 85.9±18.1 iHOT12: 96.6±17.6	20 (95.2%)	/	/	/
Lee et al ²⁴ (2012)	VAS: 8.1±1.3 (5-10) HHS: 39±6.9 (22-65) UCLA: 3.2±2.7 (2-6)	VAS: 3.1±1.4 (0-6) HHS: 82±10.2 (43-100) UCLA: 8.5±2.5 (5-10)	18 (75%) good or excellent satisfactory	4	0 (0%)	4 (16.7%)
Polesello et al ²⁵ (2015)	mHHS: 54.1 (38.5-70.4) Facial Expressions Scale: 1.8 (1-3)	mHHS: 90.4 (79.1-95.7) Facial Expressions Scale: 5.1 (4-6)	(100%)	0	0 (0%)	0 (0%)
Boyer and Dorfmann ²³ (2008)	/	63 (56.7%) had excellent or good outcomes*	/	65/111	THR: 19 (17.1%); Synovectomy: 12 (10.8%); Open removal: 11 (9.9%)	A second arthroscopy was required: 23 (20.7%); An open surgery was required: 42 (37.8%)
Ferro and Philippon ²² (2015)	mHHS: 62±15 SF12 MCS: 56±10 SF12 PCS: 41.6±8 WOMAC: 27.1±17	mHHS: 84.8±12 SF12 MCS: 55.8±5 SF12 PCS: 53±8 WOMAC: 7.2±7	(95%)	2	THR: 2 (8.7 %)	A second arthroscopy was required, then THA was required: 1 (4.3%)
Zhang et al ¹⁰ (2021)	mHHS: 67±15.7 (32-87) HOOS-Symptoms: 78.8±16 (35-100) HOOS-Pain: 80.9±14.6 (30-97) HOOS-ADL: 84.5±15.6 (33.8-98) HOOS-Sport: 50.3±18.6 (6.3-81) HOOS-QoL: 62.2±17.8 (6.3-81) VAS: 3.9±1.2 (2-7)	mHHS: 83.7±13.0 (50-91) HOOS-Symptoms: 93.3±11.5 (60-100) HOOS-Pain: 93.6±10.8 (57.5-100) HOOS-ADL: 95±9.4 (67.6-100) HOOS-Sport: 80.6±26.8 (18.8-100) HOOS-QoL: 86.7±17.1 (50-100) VAS: 1.1±1.4 (0-5)	Excellent: 33 (80.5%) Good: 7 (17.0) Fair: 1 (2.4)	2	0 (0%)	2 (4.9%)
Marchie et	/	11 (48%) had excellent or good	/	7	Perineal numbness and	A second

al ¹¹ (2011)		outcomes*			pedal paresthesia: 2 (7%)	arthroscopic procedure: 5 (17.5%); Open arthrotomy: 2 (7%)
Wu et al ²⁰ (2024)	VAS: 3.2±0.8 (2-4) HHS: 58.6±12.7 (43-73)	VAS: 0.4±0.5 (0-1) HHS: 89.8±5.3 (81-95)	100%	1	0 (0%)	0 (0%)
Bakr et al ²¹ (2024)	NAHS: 36.6±8.4 (21-48) mHHS: 37±6.3 (26-44)	NAHS: 62.38±11.23 (45-84) mHHS: 69.46±16.39 (35-84)	/	2	Femoral neurapraxia: 3 (23.1%); Osteoarthritis: 1 (7.7%)	2 (15.4%)
Zhu et al ¹⁸ (2024)	VAS: 3.8±1.2 mHHS: 66.4±14.4 NAHS: 45.2±16.2 iHOT-12: 48.4±15.6	VAS: 0.8±1.4 mHHS: 93.5±10.5 NAHS: 83.1±12.9 iHOT-12: 72.7±11.4	/	1	/	A second arthroscopy: 1 (3.6%)
Lee et al ¹⁹ (2018)	VAS: 5.4 (3-8) mHHS: 80.4 (67.0-92.4) UCLA: 4.4 (3-7) WOMAC: 24.2 (7-58)	VAS: 4 (3-5) mHHS: 90.1 (81.0-95.7) UCLA: 4.8 (3-7) WOMAC: 14.6 (0-24)	100%	0	0 (0%)	0 (0%)
Zhu et al ⁹ (2024)	VAS: 3.8±1.5 (1-7) mHHS: 65.8±12.7 (32-87) iHOT-12: 49.6±10.5 (23-74) NAHS: 46.9±7.2 (19-64)	VAS: 0.8±1.2 (0-4) mHHS: 93.5±6.7 (72-100) iHOT-12: 72.3±9.0 (49-83) NAHS: 81.7±8.6 (58-100)	/	0	0 (0%)	0 (0%)

N: number of evaluation cases; %: percentage; SD: standard deviation; mHHS: modified haris hip score; WOMAC: Western Ontario and McMaster Universities osteoarthritis index; iHOT-12: International Hip Outcome Tool; EQ-5D: EuroQoL-5 Dimension Questionnaire; VAS: visual analogue scale; NAHS: Non-Arthritic Hip Score; JOA: Japanese Orthopedic Association; iHOT-12: International Hip Outcome Tool; EQ-5D: EuroQoL-5 Dimension Questionnaire; SF-12: Short-Form 12; iHOT-12: International Hip Outcome Tool; HOOS: Hip Osteoarthritis Outcome Score; ADL: activities of daily living; QoL: Hip-Related Quality of Life; NAHS: non-arthritic hip score; UCLA: Activity Score University of California Los Angeles; /: not reported; THR: total hip replacement.

*: data are expressed as the number of evaluation cases (percentage).

ξ: Proportions in “Complications, N (%)” and “Revision, N (%)” are calculated as events/total hips among studies reporting that endpoint; 95% CIs (where shown in text) use the Wilson method. No random-effects pooling was performed.